These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 11374408)

  • 1. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Neylan JF
    Transplantation; 1997 Nov; 64(9):1277-82. PubMed ID: 9371668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes.
    David KM; Morris JA; Steffen BJ; Chi-Burris KS; Gotz VP; Gordon RD
    Clin Transplant; 2005 Apr; 19(2):279-85. PubMed ID: 15740568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients.
    Schweitzer EJ; Yoon S; Fink J; Wiland A; Anderson L; Kuo PC; Lim JW; Johnson LB; Farney AC; Weir MR; Bartlett ST
    Transplantation; 1998 Jan; 65(2):242-8. PubMed ID: 9458022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
    Jain A; Kashyap R; Dodson F; Kramer D; Hamad I; Khan A; Eghestad B; Starzl TE; Fung JJ
    Transplantation; 2001 Sep; 72(6):1091-7. PubMed ID: 11579306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of chronic renal allograft dysfunction in cyclosporine-treated patients by addition of azathioprine.
    Rocher LL; Hodgson RJ; Merion RM; Swartz RD; Keavey S; Turcotte JG; Campbell DA
    Transplantation; 1989 Feb; 47(2):249-54. PubMed ID: 2645707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid reduction with tacrolimus (CORRETA) TRIAL: a prospective Brazilian multicenter, randomized trial of early corticosteroid reduction versus regular corticosteroid dosage maintenance on a tacrolimus (Prograf) and mycophenolate mofetil (Cellcept) immunosuppression regimen in kidney transplant recipients: interim analysis.
    Garcia VD; Carvalho DB; Goncalves RT; Cavalcanti RL; Campos HH; Abbud-Filho M; Lobao-Neto AA
    Transplant Proc; 2008 Apr; 40(3):689-92. PubMed ID: 18454988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Mycophenolate Mofetil Associated With Tacrolimus for Kidney-pancreas and Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Studies.
    Datrino LN; Boccuzzi ML; Silva RM; Castilho PHBT; Riva WJ; Rocha JS; Tustumi F
    Transplant Proc; 2024 Jun; 56(5):1066-1076. PubMed ID: 38853029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection.
    Meier-Kriesche HU; Steffen BJ; Hochberg AM; Gordon RD; Liebman MN; Morris JA; Kaplan B
    Am J Transplant; 2003 Jan; 3(1):68-73. PubMed ID: 12492713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE; Fryd DS; Strand MH; Canafax DM; Ascher NL; Payne WD; Simmons RL; Najarian JS
    Am J Kidney Dis; 1985 Jun; 5(6):318-27. PubMed ID: 3893106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that addition of azathioprine improves renal function in cyclosporine-treated patients with allograft dysfunction.
    Pascual J; Marcén R; Orofino L; Quereda C; Mampaso F; Liaño F; Ortuño J
    Transplantation; 1991 Aug; 52(2):276-9. PubMed ID: 1871800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants.
    Gulanikar AC; MacDonald AS; Sungurtekin U; Belitsky P
    Transplantation; 1992 Feb; 53(2):323-8. PubMed ID: 1738926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of cyclosporine and prednisolone versus cyclosporine, azathioprine, and prednisolone in primary cadaveric renal transplantation.
    Lindholm A; Albrechtsen D; Tufveson G; Karlberg I; Persson NH; Groth CG
    Transplantation; 1992 Oct; 54(4):624-31. PubMed ID: 1412754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical analysis of racial difference with mycophenolate mofetil (MMF) dosing, clinical outcomes and adverse effects in pediatric kidney transplant patients.
    Jensen CJ; Shrivastava S; Taber DJ; Weimert NA; Shatat IF; Orak J; Chavin KD; Baliga PK
    Clin Transplant; 2011; 25(4):534-40. PubMed ID: 20636410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.
    Shapiro R; Jordan ML; Scantlebury VP; Vivas C; Marsh JW; McCauley J; Johnston J; Randhawa P; Irish W; Gritsch HA; Naraghi R; Hakala TR; Fung JJ; Starzl TE
    Transplantation; 1999 Feb; 67(3):411-5. PubMed ID: 10030287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.